Adds another patent to the Orange Book listing of Omacor®/Lovaza(TM)

5 July 2010, Lysaker: Pronova BioPharma ASA's (OSE: PRON.OL) newly issued U.S. Patent No. 7,732,488 was listed on 2 July in the Orange Book. This is the 4th patent, emanating from Pronova BioPharma's pioneering research on essential fatty acids, to be listed by the U.S. Food and Drug Administration - an achievement which further solidifies Pronova BioPharma's position as the first and only company with an EU and FDA approved Omega-3 derived prescription drug. The new patent is entitled "Pharmaceutical composition comprising low concentration of environmental pollutants." The listing of Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book, identifies drug products approved on the basis of safety and effectiveness, and may be viewed on FDA's website: "I am proud that Pronova BioPharma through our process development efforts has been able to develop a technology which removes environmental pollutants and thereby sets a new industry standard towards reductions of environmental pollutants in Omega-3s. Pronova BioPharma's technology and the newly listed composition patent ensure that our blockbuster drug Omacor®/Lovaza(TM) is available for million of patients with very low concentrations of pollutants" says CEO and President of Pronova BioPharma, Morten Jurs. Pronova BioPharma's patents, currently listed in the Orange Book, directed to Omacor®/Lovaza(TM) include: U.S. Patent Nos. 5,656,667, 5,502,077, and the newly listed 7,732,448. Additionally, the U.S. Patent and Trademark Office recently granted two process patents related to removing environmental pollutants and cholesterol (i.e., U.S. Patent Nos. 7,678,940 and 7,718,698). Pronova BioPharma's unique and complex stripping technology reduces environmental pollutants and cholesterol from oils irrespective of the quality of oil. Omacor®/Lovaza(TM) is one of the safest pharmaceutical drugs in the cardiovascular segment. Contact Morten Jurs, CEO, telephone: (+47) 22 53 49 10, email: Hamed Brodersen, VP IR and Communications, telephone: (+47) 41 74 11 22, email: About Pronova BioPharma Pronova BioPharma is a global leader in the research, development and manufacture of marine-originated omega-3 derived pharmaceutical products. Pronova BioPharma's first commercialized product is branded as Omacor® in a number of countries throughout Europe and Asia and as Lovaza(TM) in the United States. The product is manufactured, using a unique and complex process, at the Company's plants in Sandefjord, Norway and Kalundborg, Denmark. Omacor®/Lovaza(TM) is the first and only EU- and FDA-approved omega-3 derived prescription drug. The drug is prescribed as an adjunct to diet for the treatment of elevated levels of triglycerides in humans, a condition known as hypertriglyceridemia (HTG), a form of dyslipidemia (or disorder of lipid metabolism). Very high triglycerides have been linked to a number of cardiovascular diseases. Omacor® is also approved in key European and certain Asian markets for the secondary prevention of post-myocardial infarction, or Post-MI, the period following the initial survival of a heart attack. Omacor®/Lovaza(TM) has been demonstrated in a number of clinical trials to be a potent triglyceride-lowering agent as a monotherapy. It has been documented to be efficacious, safe, and highly complementary to other lipid-lowering agents, such as statins. In addition, Pronova BioPharma is involved in various projects to develop Omacor®/Lovaza(TM) in a number of cardiovascular indications, including as a combination therapy with statins for mixed dyslipidemia which management believe represents a major market opportunity for the Company. Pronova BioPharma's global network of license and distribution partners includes: GlaxoSmithKline PLC (US), Takeda Pharmaceutical (Japan), Prospa (Italy) and Solvay (UK, Germany and others). The combined sales force from this network, focused on the sale of Omacor®/Lovaza(TM), is approximately 2,650 sales representatives. Omacor®/Lovaza(TM) was launched in 2005 in the US and in major European markets, such as France and Spain. IMS Health reports that global end-user sales of the product have increased from USD144 million in 2005 to USD 1.1 billion in 2009. Pronova BioPharma had revenues of NOK 1,790 million and EBITDA of NOK 823 million in 2009. The company is listed at Oslo Børs. See for more information. Disclaimer Certain statements in this release concerning our future growth prospects are "forward-looking statements", which involve a number of risks, and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, intense competition in the pharmaceutical industry including those factors which may affect our ability to manufacture our products, our ability to attract and retain highly skilled professionals, the regulatory environment in which we operate and unauthorized use of our intellectual property and general economic conditions affecting our industry. We do not undertake to update any forward-looking statement that may be made from time to time by us or on our behalf. This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act) [HUG#1429517] This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction for further distribution is prohibited. Source: Pronova BioPharma ASA via Thomson Reuters ONE